This Case Study describes the management of a patient with a fumarate hydratase (FH)-deficient type-2 papillary renal cell carcinoma. On the basis of results fromin vitro experiments, the authors decided to treat the patient with the glycolytic inhibitor 2DG (2-deoxy-D-glucose), a new anticancer drug that is currently in clinical development.
- Toshinari Yamasaki
- Tram Anh T. Tran
- James Brugarolas
